The Effect of Targeted Delivery of Anti-Tnf-α Oligonucleotide into CD169+ Macrophages on Disease Progression in Lupus-Prone MRL/lpr Mice.

Zhen Huang,Zhengping Zhang,Yinhe Zha,Jialin Liu,Yucui Jiang,Yang,Juan Shao,Xulun Sun,Xin Cai,Yuan Yin,Jiangning Chen,Lei Dong,Junfeng Zhang

DOI: https://doi.org/10.1016/j.biomaterials.2012.06.074

IF: 14

2012-01-01

Biomaterials

Abstract:Systemic blockade of TNF-α via monoclonal antibodies and soluble receptors has shown considerable effects against several typical autoimmune disorders, but remains unconvincing for the treatment of lupus. Based on our previous study, a CD169(+) macrophage-specific therapy using TNF-α antisense oligonucleotides (ASO) was tested for its efficacy in MRL/lpr lupus-prone mice. ASO-containing cationic agarose hydrogel were injected into mice subcutaneously. Tissue distribution and cellular localization of ASO were determined. The therapeutic effects and possible mechanism were further studied in MRL/lpr lupus-prone mice. The results showed that specifically accumulation of the anti-TNF-α ASO in CD169(+) macrophages could significantly reduce TNF-α expression in CD169(+) macrophages and inhibit lymphocytes over-proliferation, finally resulted in the relief of the lupus-like symptoms of the animals. The nucleic acid drug based on CD169(+) macrophage-specific TNF-α regulation represents a potential therapeutic approach that may be valuable for lupus therapy.